228 related articles for article (PubMed ID: 30379401)
1. Afatinib as first-line treatment for advanced lung adenocarcinoma patients harboring HER2 mutation: A case report and review of the literature.
Shi Y; Wang M
Thorac Cancer; 2018 Dec; 9(12):1788-1794. PubMed ID: 30379401
[TBL] [Abstract][Full Text] [Related]
2. The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations.
Yang CJ; Tsai MJ; Hung JY; Lee MH; Tsai YM; Tsai YC; Hsu JF; Liu TC; Huang MS; Chong IW
BMC Pharmacol Toxicol; 2017 Dec; 18(1):82. PubMed ID: 29237484
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation.
Iwamoto Y; Ichihara E; Hara N; Nakasuka T; Ando C; Umeno T; Hirabae A; Maeda Y; Kiura K
Jpn J Clin Oncol; 2019 Aug; 49(8):786-788. PubMed ID: 31187861
[TBL] [Abstract][Full Text] [Related]
4. EGFR exon 18 delE709_T710insD mutated stage IV lung adenocarcinoma with response to afatinib.
Ibrahim U; Saqib A; Atallah JP
Lung Cancer; 2017 Jun; 108():45-47. PubMed ID: 28625646
[TBL] [Abstract][Full Text] [Related]
5. An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib.
Sato M; Matsui A; Shimoyama Y; Omote N; Morise M; Hase T; Tanaka I; Suzuki K; Hasegawa Y
Intern Med; 2018 Dec; 57(23):3429-3432. PubMed ID: 30101911
[TBL] [Abstract][Full Text] [Related]
6. Afatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with Rare EGFR (in exon 18-T179X) Mutation - a Case Report.
Čoupková H; Vyzula R
Klin Onkol; 2018; 31(5):380-383. PubMed ID: 30541326
[TBL] [Abstract][Full Text] [Related]
7. Major Clinical Response to Afatinib Monotherapy in Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion Mutation.
Urbán L; Dóczi R; Vodicska B; Tihanyi D; Horváth M; Kormos D; Takács I; Pápai-Székely Z; Póka-Farkas Z; Várkondi E; Schwáb R; Hegedüs C; Vályi-Nagy I; Peták I
Clin Lung Cancer; 2021 Jan; 22(1):e112-e115. PubMed ID: 33082101
[No Abstract] [Full Text] [Related]
8. Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib.
Yamaoka T; Ohba M; Matsunaga Y; Tsurutani J; Ohmori T
J Vis Exp; 2019 Jun; (148):. PubMed ID: 31305510
[TBL] [Abstract][Full Text] [Related]
9. Identification of a Novel MET Exon 14 Skipping Variant Coexistent with EGFR Mutation in Lung Adenocarcinoma Sensitive to Combined Treatment with Afatinib and Crizotinib.
Zeng L; Xia C; Zhang Y; Yang N
J Thorac Oncol; 2019 Apr; 14(4):e70-e72. PubMed ID: 30922580
[No Abstract] [Full Text] [Related]
10. Therapies after first-line afatinib in patients with
Yoshioka H; Kato T; Okamoto I; Tanaka H; Hida T; Seto T; Kiura K; Tian Y; Azuma H; Yamamoto N
Future Oncol; 2020 Feb; 16(4):49-60. PubMed ID: 31922425
[No Abstract] [Full Text] [Related]
11. Efficacy generated by afatinib in a lung adenocarcinoma patient harboring HER2 S310Y mutation.
Wang J; Wen Y; Ding G; Ding P; Zhang L; Liu J; Zhang T; Yang L
Cancer Biol Ther; 2018 Jun; 19(6):450-453. PubMed ID: 29561699
[TBL] [Abstract][Full Text] [Related]
12. Combined therapy with osimertinib and afatinib in a lung adenocarcinoma patient with EGFR T790M mutation and multiple HER2 alterations after resistance to icotinib: A case report.
Zhang P; Nie X; Wang B; Li L
Thorac Cancer; 2018 Dec; 9(12):1774-1777. PubMed ID: 30295016
[TBL] [Abstract][Full Text] [Related]
13. Treatment effectiveness and tolerability of afatinib at different doses in patients with EGFR-mutated lung adenocarcinoma: How low can we go?
Lim CK; Wei YF; Tsai MS; Chen KY; Shih JY; Yu CJ
Eur J Cancer; 2018 Nov; 103():32-40. PubMed ID: 30199768
[TBL] [Abstract][Full Text] [Related]
14. Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations.
Chen YC; Tsai MJ; Lee MH; Kuo CY; Shen MC; Tsai YM; Chen HC; Hung JY; Huang MS; Chong IW; Yang CJ
BMC Cancer; 2021 May; 21(1):495. PubMed ID: 33941115
[TBL] [Abstract][Full Text] [Related]
15. Successful Treatment of Lung Adenocarcinoma with Epidermal Growth Factor Receptor Compound Mutations Involving Exon 19 Deletion and Exon 20 Insertion by Afatinib.
Ikeuchi T; Tokuyasu H; Ishikawa S
Intern Med; 2019; 58(1):101-104. PubMed ID: 30606938
[TBL] [Abstract][Full Text] [Related]
16. Afatinib for the first-line treatment of
Tu HY; Wu YL
Future Oncol; 2020 Nov; 16(31):2569-2586. PubMed ID: 32927981
[TBL] [Abstract][Full Text] [Related]
17. Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature.
Xu H; Liang Q; Xu X; Tan S; Wang S; Liu Y; Liu L
World J Surg Oncol; 2021 Nov; 19(1):330. PubMed ID: 34794435
[TBL] [Abstract][Full Text] [Related]
18. Afatinib Achieved Remarkable Disease Control in a Chinese Patient With Lung Adenocarcinoma Harboring Rare EGFR Exon 18-25 Kinase Domain Duplication.
Wang XF; Zhao QT; Chen C
Am J Ther; 2020; 27(5):e535-e537. PubMed ID: 31567148
[No Abstract] [Full Text] [Related]
19. Afatinib and Cetuximab in Four Patients With EGFR Exon 20 Insertion-Positive Advanced NSCLC.
van Veggel B; de Langen AJ; Hashemi SMS; Monkhorst K; Heideman DAM; Thunnissen E; Smit EF
J Thorac Oncol; 2018 Aug; 13(8):1222-1226. PubMed ID: 29702285
[TBL] [Abstract][Full Text] [Related]
20. EGFR exon 18 DelE709_T710insD as an Acquired Resistance Mechanism to Afatinib in an Advanced EGFR exon 18 E709H Lung Adenocarcinoma.
Zeng L; Zhang Y; Yang N
J Thorac Oncol; 2018 Jun; 13(6):e93-e95. PubMed ID: 29793651
[No Abstract] [Full Text] [Related]
[Next] [New Search]
